CoChat

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

Open access
Ringelstein, Marius, Ayzenberg, Ilya, Lindenblatt, Gero, Fischer, Katinka, Gahlen, Anna, Novi, Giovanni, Hayward-Könnecke, Helen, Schippling, Sven, Rommer, Paulus S., Kornek, Barbara, Zrzavy, Tobias, Biotti, Damien, Ciron, Jonathan, Audoin, Bertrand, Berthele, Achim, Giglhuber, Katrin, Zephir, Helene, Kümpfel, Tania, Berger, Robert, Röther, Joachim, Häußler, Vivien, Stellmann, Jan-Patrick, Whittam, Daniel, Jacob, Anu, Kraemer, Markus, Gueguen, Antoine, Deschamps, Romain, Bayas, Antonios, Hümmert, Martin W., Trebst, Corinna, Haarmann, Axel, Jarius, Sven, Wildemann, Brigitte, Grothe, Matthias, Siebert, Nadja, Ruprecht, Klemens, Paul, Friedemann, Collongues, Nicolas, Marignier, Romain, Levy, Michael, Karenfort, Michael, Deppe, Michael, Albrecht, Philipp, Hellwig, Kerstin, Gold, Ralf, Hartung, Hans-Peter, Meuth, Sven G., Kleiter, Ingo, Aktas, Orhan, on behalf of the Neuromyelitis Optica Study Group (NEMOS) · 2022 · Neurology Neuroimmunology & Neuroinflammation
Cited by 160

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background and Objectives To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–IgG–associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD). Methods Annualized relapse rate (ARR), Expanded Disability Status Scale score, MRI, autoantibody titers, pain, and adverse events were retrospectively evaluated in 57 patients with MOGAD (n = 14), aquaporin-4 (AQP4)-IgG seropositive (n = 36), and seronegative NMOSD (n = 7; 12%), switched to TCZ from previous immunotherapies, particularly rituximab. Results Patients received TCZ for 23.8 months (median; interquartile range 13.0–51.1 months), with an IV dose of 8.0 mg/kg (median; range 6–12 mg/kg) every 31.6 days (mean; range 26–44 days). For MOGAD, the median ARR decreased from 1.75 (range 0.5–5) to 0 (range 0–0.9; p = 0.0011) under TCZ. A similar effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0–5] to 0 [range 0–4.2]; p < 0.001) and for seronegative NMOSD (from 3.0 [range 1.0–3.0] to 0.2 [range 0–2.0]; p = 0.031). During TCZ, 60% of all patients were relapse free (79% for MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI inflammatory activity decreased in MOGAD (p = 0.04; for the brain) and in AQP4-IgG+ NMOSD (p < 0.001; for the spinal cord). Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (n = 44), ARR reductions were confirmed, including the subgroups of MOGAD (n = 11) and AQP4-IgG+ patients (n = 28). Similarly, in the group of patients treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40% for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no advantage compared with TCZ monotherapy. Discussion This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/nxi.0000000000001100

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 160

Metadata

Authors
Ringelstein, M., Ayzenberg, I., Lindenblatt, G., Fischer, K., Gahlen, A., Novi, G., Hayward-Könnecke, H., Schippling, S., Rommer, P. S., Kornek, B., Zrzavy, T., Biotti, D., Ciron, J., Audoin, B., Berthele, A., Giglhuber, K., Zephir, H., Kümpfel, T., Berger, R., Röther, J., Häußler, V., Stellmann, J.-P., Whittam, D., Jacob, A., Kraemer, M., Gueguen, A., Deschamps, R., Bayas, A., Hümmert, M. W., Trebst, C., Haarmann, A., Jarius, S., Wildemann, B., Grothe, M., Siebert, N., Ruprecht, K., Paul, F., Collongues, N., Marignier, R., Levy, M., Karenfort, M., Deppe, M., Albrecht, P., Hellwig, K., Gold, R., Hartung, H.-P., Meuth, S. G., Kleiter, I., Aktas, O., & on behalf of the Neuromyelitis Optica Study Group (NEMOS)
Venue
Neurology Neuroimmunology & Neuroinflammation
Published
2022-01
Volume
9
Issue
1
ISSN
2332-7812 (ISSN-L)
OpenAlex
W3214450061
Cited by
160
References
6
FWCI
13.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders. https://app.cochat.ai/papers/10.1212/nxi.0000000000001100
The paper
Ringelstein, M., Ayzenberg, I., Lindenblatt, G., Fischer, K., Gahlen, A., Novi, G., Hayward-Könnecke, H., Schippling, S., Rommer, P. S., Kornek, B., Zrzavy, T., Biotti, D., Ciron, J., Audoin, B., Berthele, A., Giglhuber, K., Zephir, H., Kümpfel, T., Berger, R., . . . on behalf of the Neuromyelitis Optica Study Group (NEMOS). (2022). Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000001100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.